glp 1 drugs thyroid cancer Do GLP-1 Weight-Loss Shots Really Raise Risk? With the rapid expansion of GLP-1 medications for diabetes and weight loss, public concern has grown regarding a possible link to thyroid cancer 10 Surprising Facts About GLP-1/GIP

Retatrutide, a new weight-loss drug, helped people lose 30% of their body weight in a study, rivaling results seen with weight-loss surgery.

The answer is yes

These findings support their use as a valuable adjunctive obesity management medication (OMMs) in post-bariatric care, though long-term adherence and cost-effectiveness require further investigation

The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity

Further research is warranted to explore long-term outcomes and optimize treatment protocols for this patient population